Reply by L. Maffioli

  • Lorenzo Maffioli
  • Luca Dellavedova
  • Luigia Florimonte
Reply

References

  1. 1.
    Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805–13.CrossRefPubMedGoogle Scholar
  2. 2.
    Kuroda I. Strontium-89 for prostate cancer with bone metastases: the potential of cancer control and improvement of overall survival. Ann Nucl Med. 2014;28:11–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer Clin Oncol. 1991;9:1084–6.CrossRefGoogle Scholar
  4. 4.
    Biersack H-J, Palmedo H, Andris A, et al. Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med. 2011;52:1721–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Tu S-M, Millikan RE, Mengistu B, et al. Bone targeted therapy for advanced androgen-indipendent carcinoma of the prostate: a randomized phase II trial. Lancet. 2001;357:336–41.CrossRefPubMedGoogle Scholar
  6. 6.
    Ricci S, Boni G, Pastina I, et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:1023–30.CrossRefPubMedGoogle Scholar
  7. 7.
    Zlotta AR, Schulman CC. Can survival be prolonged for patients with hormone-resistant prostate cancer? Lancet. 2001;357:326–7 (Commentary).CrossRefPubMedGoogle Scholar
  8. 8.
    Maini CL, Bergomi S, Romano L, Sciuto R. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging. 2004;31 Suppl 1:171–8.CrossRefGoogle Scholar
  9. 9.
    Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate cancer: a phase I/II trial. J Nucl Med. 1993;34:1839–44.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Lorenzo Maffioli
    • 1
  • Luca Dellavedova
    • 1
  • Luigia Florimonte
    • 2
  1. 1.Nuclear Medicine DepartmentA.S.S.T. Ovest MilaneseLegnanoItaly
  2. 2.Nuclear Medicine DepartmentFondazione IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoMilanoItaly

Personalised recommendations